Buy Or Sell Opportunity • 13h
Now 21% undervalued after recent price drop Over the last 90 days, the stock has fallen 2.2% to €234. The fair value is estimated to be €295, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 8.8% per annum. Earnings are also forecast to grow by 21% per annum over the same time period. Reported Earnings • Apr 24
First quarter 2026 earnings released First quarter 2026 results: Revenue: €899.1m (up 1.8% from 1Q 2025). Net income: €56.2m (up 16% from 1Q 2025). Profit margin: 6.3% (up from 5.5% in 1Q 2025). The increase in margin was driven by higher revenue. Revenue is forecast to grow 8.7% p.a. on average during the next 3 years, compared to a 9.6% growth forecast for the Life Sciences industry in Europe. Buy Or Sell Opportunity • Apr 23
Now 22% undervalued after recent price drop Over the last 90 days, the stock has fallen 18% to €213. The fair value is estimated to be €271, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 5.3% over the last 3 years. Earnings per share has declined by 71%. For the next 3 years, revenue is forecast to grow by 8.3% per annum. Earnings are also forecast to grow by 21% per annum over the same time period. New Risk • Apr 20
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Austrian stocks, typically moving 7.1% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (7.1% average weekly change). Minor Risk High level of debt (91% net debt to equity). Declared Dividend • Mar 16
Dividend of €0.74 announced Dividend of €0.74 is the same as last year. Ex-date: 27th March 2026 Payment date: 31st March 2026 Dividend yield will be 0.4%, which is lower than the industry average of 0.5%. Payout Ratios Payout ratio: 33%. Cash payout ratio: 13%. New Risk • Feb 17
New major risk - Financial position The company's interest payments are not well covered by earnings. Net interest cover: 2.6x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. This is currently the only risk that has been identified for the company. Annuncio • Feb 17
Sartorius Aktiengesellschaft, Annual General Meeting, Mar 26, 2026 Sartorius Aktiengesellschaft, Annual General Meeting, Mar 26, 2026, at 12:00 W. Europe Standard Time. New Risk • Feb 13
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Austrian stocks, typically moving 4.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks High level of debt (95% net debt to equity). Share price has been volatile over the past 3 months (4.6% average weekly change). Declared Dividend • Feb 13
Dividend of €0.74 announced Dividend of €0.74 is the same as last year. Ex-date: 27th March 2026 Payment date: 31st March 2026 Dividend yield will be 0.3%, which is lower than the industry average of 0.5%. Payout Ratios Payout ratio: 61%. Cash payout ratio: 11%. Declared Dividend • Feb 09
Dividend of €0.74 announced Dividend of €0.74 is the same as last year. Ex-date: 27th March 2026 Payment date: 31st March 2026 Dividend yield will be 0.3%, which is lower than the industry average of 0.5%. Payout Ratios Payout ratio: 61%. Cash payout ratio: 11%. Annuncio • Feb 07
Sartorius Aktiengesellschaft announces Annual dividend, payable on March 31, 2026 Sartorius Aktiengesellschaft announced Annual dividend of EUR 0.7400 per share payable on March 31, 2026, ex-date on March 27, 2026 and record date on March 30, 2026. Annuncio • Feb 05
Sartorius AG Provides Earnings Guidance for the Fiscal Year 2026 Sartorius AG provided earnings guidance for the fiscal year 2026. For the year, the company expects its profitable growth trajectory to continue, with a continued positive development in the Bioprocess Solutions Division and a recovery in the Lab Products & Services Division. Buy Or Sell Opportunity • Feb 04
Now 22% undervalued Over the last 90 days, the stock has risen 9.5% to €245. The fair value is estimated to be €315, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 8.2% per annum. Earnings are also forecast to grow by 23% per annum over the same time period. Annuncio • Jan 28
Sartorius Aktiengesellschaft to Report Fiscal Year 2025 Final Results on Feb 16, 2026 Sartorius Aktiengesellschaft announced that they will report fiscal year 2025 final results at 12:00 PM, Central European Standard Time on Feb 16, 2026 Annuncio • Jan 16
Sartorius Expands Bio-Circular Product Offering for More Sustainable Bioprocesses Sartorius AG expanded bio-circular product offering for more sustainable bioprocesses. Further production hubs in Germany and Tunisia now certified by International Sustainability and Carbon Certification. Certified raw materials significantly reduce dependence on fossil-based plastics. Bio-circular filters and additional single-use fluid management technologies now available for biopharma manufacturers. Certified production network spans sites in Germany, Tunisia, France and the UK. With ISCC Plus certification now extended to its sites in Gottingen, Germany, and M'Hamdia, Tunisia, the company can use certified renewable raw materials in additional product lines, reducing the share of fossil-based plastics while ensuring full compatibility with existing bioprocesses. ISCC Plus is a global standard for renewable and recycled raw materials that ensures transparent and traceable sourcing and compliance across the value chain based on a mass-balance system. At its Gottingen headquarters, Sartorius will produce the PFAS-free filter Sartopore Evo using ISCC Plus-certified materials. In M'Hamdia, selected Flexsafe bags will be manufactured with certified second generation feedstock. The use of ISCC Plus-certified material enables a reduction of fossil-based compounds by around 70% in the Flexsafe film and by an average 40-60% in Sartopore Evo filters. Earlier in 2025, Sartorius achieved ISCC Plus certification for its sites in Aubagne, France, and Stonehouse, United Kingdom, covering its Ambr bioreactor vessels, Vivaflow filters, and selected Flexsafe bags for the manufacture of biopharmaceutical. The company plans to expand the use of certified renewable raw materials across its global production network. New Risk • Dec 12
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Austrian stocks, typically moving 5.2% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (5.2% average weekly change). Minor Risk High level of debt (95% net debt to equity). Buy Or Sell Opportunity • Dec 12
Now 21% undervalued Over the last 90 days, the stock has risen 26% to €244. The fair value is estimated to be €310, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 8.7% per annum. Earnings are also forecast to grow by 27% per annum over the same time period. Reported Earnings • Oct 17
Third quarter 2025 earnings released Third quarter 2025 results: Revenue: €843.2m (up 6.3% from 3Q 2024). Net income: €43.8m (up 209% from 3Q 2024). Profit margin: 5.2% (up from 1.8% in 3Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 9.0% p.a. on average during the next 3 years, compared to a 9.7% growth forecast for the Life Sciences industry in Europe. Annuncio • Oct 17
Sartorius Aktiengesellschaft Revises Financial Guidance for the Year 2025 Sartorius Aktiengesellschaft revised financial guidance for the year 2025. Based on the year-to-date results and taking into account the anticipated impact of existing tariffs, the contributions from the MATTEK acquisition, as well as the strong basis for comparison in the fourth quarter of 2024, management further sharpens its full-year guidance for the Group and both divisions. The company now expects sales revenue growth at Group level of around 7% (previously: around 6% organic growth with a forecast range of about plus/minus two percentage points). This includes an inorganic growth contribution of around 0.3%. New Risk • Sep 12
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Austrian stocks, typically moving 4.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks High level of debt (96% net debt to equity). Share price has been volatile over the past 3 months (4.6% average weekly change). Reported Earnings • Jul 24
Second quarter 2025 earnings released Second quarter 2025 results: Revenue: €884.3m (up 2.7% from 2Q 2024). Net income: €32.5m (up 35% from 2Q 2024). Profit margin: 3.7% (up from 2.8% in 2Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 9.1% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. New Risk • Jul 04
New major risk - Revenue and earnings growth Earnings have declined by 6.0% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 6.0% per year over the past 5 years. Minor Risks High level of debt (93% net debt to equity). Share price has been volatile over the past 3 months (6.3% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (2.8% net profit margin). New Risk • May 27
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Austrian stocks, typically moving 7.5% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (7.5% average weekly change). Minor Risks High level of debt (93% net debt to equity). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (2.8% net profit margin). Annuncio • Apr 17
Sartorius Aktiengesellschaft Provides Earnings Guidance for the Fiscal 2025 Sartorius Aktiengesellschaft provided earnings guidance for the fiscal 2025. For the period, Based on the first quarter results and the expected good underlying market development, management projects sales revenue growth of around 6% for the Group, around 7% for the Bioprocess Solutions division and around 1% for Lab Products & Services for 2025. Due to the continued above-average volatility, the company currently anticipates a forecast range of about plus/minus two percentage points respectively. Reported Earnings • Apr 16
First quarter 2025 earnings released First quarter 2025 results: EPS: €0.70. Revenue: €883.0m (up 7.7% from 1Q 2024). Net income: €48.5m (up 32% from 1Q 2024). Profit margin: 5.5% (up from 4.5% in 1Q 2024). Revenue is forecast to grow 8.9% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Annuncio • Mar 29
Sartorius Ag Approves Ordinary Dividend, Payable on April 1, 2025 Sartorius AG at its AGM held on March 27, 2025, approved the dividend of 0.73 euros per ordinary share. The total amount disbursed will be 50.7 million euros, with the dividend to be paid out to shareholders on April 1, 2025. Buy Or Sell Opportunity • Mar 20
Now 21% undervalued Over the last 90 days, the stock has risen 11% to €241. The fair value is estimated to be €303, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 5.1% over the last 3 years. Earnings per share has declined by 48%. For the next 3 years, revenue is forecast to grow by 9.2% per annum. Earnings are also forecast to grow by 27% per annum over the same time period. Declared Dividend • Mar 17
Dividend of €0.74 announced Dividend of €0.74 is the same as last year. Ex-date: 28th March 2025 Payment date: 1st April 2025 Dividend yield will be 0.3%, which is lower than the industry average of 0.5%. Payout Ratios Payout ratio: 61%. Cash payout ratio: 9%. Buy Or Sell Opportunity • Mar 03
Now 21% undervalued Over the last 90 days, the stock has risen 11% to €236. The fair value is estimated to be €298, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 5.1% over the last 3 years. Earnings per share has declined by 48%. For the next 3 years, revenue is forecast to grow by 9.2% per annum. Earnings are also forecast to grow by 27% per annum over the same time period. New Risk • Feb 19
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 24% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (2.7x net interest cover). Minor Risks Share price has been volatile over the past 3 months (5.6% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (2.5% net profit margin). Annuncio • Feb 18
Sartorius Aktiengesellschaft, Annual General Meeting, Mar 27, 2025 Sartorius Aktiengesellschaft, Annual General Meeting, Mar 27, 2025. Reported Earnings • Feb 17
Full year 2024 earnings released: EPS: €1.21 (vs €3.00 in FY 2023) Full year 2024 results: EPS: €1.21 (down from €3.00 in FY 2023). Revenue: €3.38b (flat on FY 2023). Net income: €84.0m (down 59% from FY 2023). Profit margin: 2.5% (down from 6.0% in FY 2023). Revenue is forecast to grow 9.1% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has fallen by 48% per year but the company’s share price has only fallen by 14% per year, which means it has not declined as severely as earnings. Declared Dividend • Feb 17
Dividend of €0.74 announced Dividend of €0.74 is the same as last year. Ex-date: 28th March 2025 Payment date: 1st April 2025 Dividend yield will be 0.3%, which is lower than the industry average of 0.5%. Payout Ratios Payout ratio: 65%. Cash payout ratio: 11%. Annuncio • Feb 09
Sartorius AG Proposes Ordinary Dividend for Fiscal 2024, Payable on April 1, 2025 The Supervisory Board of Sartorius AG resolved at its meeting held on February 7, 2025 to approve the recommendation of the Executive Board to submit a proposal to the Annual General Meeting on March 27, 2025, to pay a dividend of EUR 0.73 per ordinary share for fiscal 2024, the same amount as for the previous year. The dividend will be paid on April 1, 2025. Annuncio • Nov 16
Sartorius Aktiengesellschaft to Report Fiscal Year 2024 Results on Jan 28, 2025 Sartorius Aktiengesellschaft announced that they will report fiscal year 2024 results on Jan 28, 2025 Buy Or Sell Opportunity • Nov 06
Now 21% undervalued after recent price drop Over the last 90 days, the stock has fallen 4.9% to €229. The fair value is estimated to be €289, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 9.4% per annum. Earnings are also forecast to grow by 37% per annum over the same time period. Reported Earnings • Oct 17
Third quarter 2024 earnings released Third quarter 2024 results: EPS: €0.21. Revenue: €793.6m (down 2.1% from 3Q 2023). Net income: €14.2m (up 65% from 3Q 2023). Profit margin: 1.8% (up from 1.1% in 3Q 2023). The increase in margin was driven by lower expenses. Revenue is forecast to grow 9.7% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has fallen by 51% per year but the company’s share price has only fallen by 22% per year, which means it has not declined as severely as earnings. Annuncio • Sep 19
Labforward GmbH acquired LabTwin GmbH from Sartorius Aktiengesellschaft (XTRA:SRT3). Labforward GmbH acquired LabTwin GmbH from Sartorius Aktiengesellschaft (XTRA:SRT3) on September 17, 2024. Sartorius will become a shareholder in labforward GmbH post the transaction. The merged company will be led by Joerg Hoffmann of labforward GmbH. The future headquarters will be the previous location of LabTwin in Berlin.
Labforward GmbH completed the acquisition of LabTwin GmbH from Sartorius Aktiengesellschaft (XTRA:SRT3) on September 17, 2024. Reported Earnings • Jul 20
Second quarter 2024 earnings released Second quarter 2024 results: Revenue: €860.7m (up 3.4% from 2Q 2023). Net income: €23.9m (down 75% from 2Q 2023). Profit margin: 2.8% (down from 11% in 2Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Buy Or Sell Opportunity • May 16
Now 22% undervalued after recent price drop Over the last 90 days, the stock has fallen 18% to €277. The fair value is estimated to be €355, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 11% per annum. Earnings are also forecast to grow by 28% per annum over the same time period. Reported Earnings • Apr 18
First quarter 2024 earnings released First quarter 2024 results: Revenue: €819.6m (down 9.3% from 1Q 2023). Net income: €36.7m (down 61% from 1Q 2023). Profit margin: 4.5% (down from 10% in 1Q 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Life Sciences industry in Europe. Upcoming Dividend • Mar 26
Upcoming dividend of €0.74 per share Eligible shareholders must have bought the stock before 02 April 2024. Payment date: 04 April 2024. Payout ratio is a comfortable 25% and this is well supported by cash flows. Trailing yield: 0.2%. Lower than top quartile of Austrian dividend payers (5.8%). Lower than average of industry peers (0.6%). Declared Dividend • Feb 19
Dividend of €0.74 announced Shareholders will receive a dividend of €0.74. Ex-date: 2nd April 2024 Payment date: 4th April 2024 Dividend yield will be 0.2%, which is lower than the industry average of 0.5%. Payout Ratios Payout ratio: 25%. Cash payout ratio: 17%. Reported Earnings • Feb 18
Full year 2023 earnings released: EPS: €3.00 (vs €9.91 in FY 2022) Full year 2023 results: EPS: €3.00 (down from €9.91 in FY 2022). Revenue: €3.40b (down 19% from FY 2022). Net income: €205.2m (down 70% from FY 2022). Profit margin: 6.0% (down from 16% in FY 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 9.8% p.a. on average during the next 3 years, compared to a 9.8% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings. Annuncio • Feb 03
Sartorius Aktiengesellschaft to Report Fiscal Year 2023 Final Results on Feb 16, 2024 Sartorius Aktiengesellschaft announced that they will report fiscal year 2023 final results at 7:00 AM, Central European Standard Time on Feb 16, 2024 Annuncio • Jan 18
Sartorius Aktiengesellschaft to Report Fiscal Year 2023 Results on Jan 26, 2024 Sartorius Aktiengesellschaft announced that they will report fiscal year 2023 results at 7:00 AM, Central European Standard Time on Jan 26, 2024 Valuation Update With 7 Day Price Move • Nov 06
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to €257, the stock trades at a forward P/E ratio of 49x. Average forward P/E is 25x in the Life Sciences industry in Europe. Total loss to shareholders of 36% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €238 per share. Annuncio • Oct 20
Sartorius Aktiengesellschaft, Annual General Meeting, Mar 28, 2024 Sartorius Aktiengesellschaft, Annual General Meeting, Mar 28, 2024. Reported Earnings • Oct 20
Third quarter 2023 earnings released Third quarter 2023 results: Revenue: €810.7m (down 23% from 3Q 2022). Net income: €8.60m (down 94% from 3Q 2022). Profit margin: 1.1% (down from 15% in 3Q 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 9.9% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Valuation Update With 7 Day Price Move • Oct 17
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to €265, the stock trades at a forward P/E ratio of 47x. Average forward P/E is 24x in the Life Sciences industry in Europe. Total loss to shareholders of 31% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €251 per share. Annuncio • Oct 13
Sartorius Ag Lowers Earnings Forecast for the Fiscal Year 2023 SARTORIUS AG lowered earnings forecast for the fiscal year 2023. For the year, Group sales revenue is expected to decline by around 17 percent; excluding Covid-19-related business, revenue would decline by around 12% (previously: sales revenue decline in the low to mid-teens percentage range; excluding Covid-19-related business, decline in the mid to high single-digit percentage range). Acquisitions are still expected to contribute around 2 percentage points to the sales revenue development. Reported Earnings • Jul 26
Second quarter 2023 earnings released Second quarter 2023 results: Revenue: €832.0m (down 20% from 2Q 2022). Net income: €95.0m (down 43% from 2Q 2022). Profit margin: 11% (down from 16% in 2Q 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Life Sciences industry in Europe. Valuation Update With 7 Day Price Move • Jul 24
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to €359, the stock trades at a forward P/E ratio of 65x. Average forward P/E is 27x in the Life Sciences industry in Europe. Total returns to shareholders of 11% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €224 per share. Reported Earnings • Apr 23
First quarter 2023 earnings released First quarter 2023 results: EPS: €1.36. Revenue: €903.2m (down 12% from 1Q 2022). Net income: €93.1m (down 55% from 1Q 2022). Profit margin: 10% (down from 20% in 1Q 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Life Sciences industry in Europe. Upcoming Dividend • Mar 23
Upcoming dividend of €1.44 per share at 0.4% yield Eligible shareholders must have bought the stock before 30 March 2023. Payment date: 03 April 2023. Payout ratio is a comfortable 15% and this is well supported by cash flows. Trailing yield: 0.4%. Lower than top quartile of Austrian dividend payers (5.5%). Lower than average of industry peers (0.7%). Reported Earnings • Feb 20
Full year 2022 earnings released Full year 2022 results: Revenue: €4.17b (up 21% from FY 2021). Net income: €678.1m (up 113% from FY 2021). Profit margin: 16% (up from 9.2% in FY 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 9.5% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Life Sciences industry in Europe. Annuncio • Jan 27
Sartorius Aktiengesellschaft Provides Revenue Guidance for the Full Year 2023 Sartorius Aktiengesellschaft provided revenue guidance for the full year 2023. Consolidated sales revenue is expected to increase by an amount in the low single-digit percentage range. Excluding the Covid-19-related business, the increase would be in the high single-digit percentage range. Acquisitions are anticipated to contribute around 1% point to growth. Annuncio • Jan 04
Sartorius Announces Management Changes for Sartorius North America Sartorius announced Maurice Phelan has assumed the role of President of Sartorius North America. He succeeds Mary Lavin, who has retired after nearly 35 years. Sartorius North America, headquartered in Bohemia, New York, currently employs more than 3,000 employees across 17 sites in the United States and Canada. Mr. Phelan has spent many years in the industry and recently rejoined Sartorius from Repligen, where he was Vice President of Fluid Management. Before that, he served as Head of Operations of the Sartorius site in Marlborough, Massachusetts. Previously, he held leadership roles at GE Healthcare and Merck Millipore. Mr. Phelan holds degrees in chemistry and experimental physics from the National University of Ireland. Valuation Update With 7 Day Price Move • Nov 10
Investor sentiment improved over the past week After last week's 21% share price gain to €401, the stock trades at a forward P/E ratio of 44x. Average forward P/E is 33x in the Life Sciences industry in Europe. Total returns to shareholders of 126% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €201 per share. Annuncio • Jul 21
Sartorius Aktiengesellschaft Confirms Consolidated Financial Guidance for the Year 2022 Sartorius Aktiengesellschaft confirmed consolidated financial guidance for the year 2022. Consolidated sales revenue is expected to increase by about 15% to 19%, with non-organic growth from acquisitions projected to contribute about 2% points. Annuncio • Feb 11
Sartorius AG Proposes Ordinary Dividend for the Year 2021 The Supervisory Board of Sartorius AG resolved at its meeting held on February 10, 2022 to approve the recommendation of the Executive Board to submit a proposal to the Annual General Shareholders' Meeting on March 25, 2022, to pay dividends of 1.26 euros per preference share and 1.25 euros per ordinary share. Under this proposal, the total distributed profit would be 85.9 million euros. In the prior year, dividends were 0.71 euros per preference share and 0.70 euros per ordinary share. Annuncio • Jan 28
Sartorius Aktiengesellschaft Provides Consolidated Sales Revenue Guidance for the Fiscal Year 2022 and Reaffirms Consolidated Sales Revenue for the Year 2025 Sartorius Aktiengesellschaft provided consolidated sales revenue guidance for the fiscal year 2022. The company expects dynamic performance for the full year of 2022 as well. Consolidated sales revenue is thus projected to increase by about 14% to 18%. Regarding pandemic-related business, the company projects sales revenue for 2022 at about the previous year's level of around EUR 500 million.The consolidated sales revenue target for 2025 had already been substantially raised at the beginning of 2021 and remains unchanged at around EUR 5 billion. The mid-term targets for 2025 still do not include any pandemic-related business as management currently considers such estimates to be too uncertain. Annuncio • Dec 17
Sartorius Aktiengesellschaft (XTRA:SRT) entered into an agreement to acquire a 62.5% stake in ALS Automated Lab Solutions GmbH. Sartorius Aktiengesellschaft (XTRA:SRT) entered into an agreement to acquire a 62.5% stake in ALS Automated Lab Solutions GmbH on December 16, 2021. Sartorius Aktiengesellschaft (XTRA:SRT) is initially purchasing 62.5 percent of the shares in ALS Automated Lab Solutions GmbH. The remaining 37.5 percent will be acquired in 2026. ALS Automated Lab Solutions GmbH currently employs around 30 people and is expected to generate sales in the high single-digit million-euro area in 2021, with a double-digit EBITDA margin. Annuncio • Jul 07
Sartorius Provides Earnings Guidance for the First Half Ended June 30, 2021 Sartorius provided earnings guidance for the first half ended June 30, 2021. For the first six months ended June 30, 2021, the company expects revenue growth to be approximately 60% in constant currencies. Revenue of the Bioprocess Solutions Division is anticipated to grow by around 63%. Annuncio • Jul 06
Sartorius Raises Group Earnings Guidance for the Full Year 2021 Sartorius raised group earnings guidance for the full year 2021. The company now projects consolidated sales growth of around 45% (previously 35%). For the Bioprocess Solutions Division, sales are anticipated to increase by about 50% (previously 40%). Sales growth for the Lab Products & Services Division is now expected to be 30% (previously 20%). Annuncio • Jul 04
Sartorius Plans to Acquire Remaining Shares of Cellgenix Sartorius Aktiengesellschaft (XTRA:SRT) has initially acquired 51% of Cellgenix, which has been privately owned until now, for around EUR 100 million in cash. Sartorius strengthens product portfolio for cell and gene therapies by acquiring a majority stake in Cellgenix. At beginning of 2023 and 2026, Sartorius plans to acquire remaining shares of Cellgenix. Annuncio • Apr 23
Sartorius AG Raises Revenue Guidance for the Year 2021 Sartorius AG raised revenue guidance for 2021. For the period, the management confirmed its growth forecast for fiscal 2021, which had been raised in mid-March based on very strong order intake and high demand anticipated to continue in the further course of the year. Accordingly, management projects consolidated sales growth of around 35% (of which 5.5% points are expected to be contributed by acquisitions and about 16% points by business related to the coronavirus pandemic). Annuncio • Mar 19
Sartorius Revises Earnings Guidance for the Year 2021 Sartorius revised earnings guidance for the year 2021. Based on very strong order intake during the first 10 weeks of 2021 and high demand expected to continue in the further course of the year, the company has raised its growth forecast for both divisions and, therefore, for the entire Group for fiscal 2021. Against the backdrop of higher sales expectations and significant economies of scale, the company's earnings outlook has also been raised. Management now projects consolidated sales growth of around 35% (previously 19% to 25%) and an underlying EBITDA margin1 of about 32% (previously about 30.5%) for the Group. Annuncio • Jan 27
Sartorius Aktiengesellschaft to Report Fiscal Year 2020 Final Results on Feb 18, 2021 Sartorius Aktiengesellschaft announced that they will report fiscal year 2020 final results on Feb 18, 2021 Annuncio • Sep 25
Sartorius Aktiengesellschaft to Report Q3, 2020 Results on Oct 20, 2020 Sartorius Aktiengesellschaft announced that they will report Q3, 2020 results on Oct 20, 2020 Annuncio • Jul 30
Sartorius Aktiengesellschaft (XTRA:SRT) and Sartorius Stedim Biotech S.A. (ENXTPA:DIM) completed the acquisition of certain businesses from Danaher Corporation (NYSE:DHR). Sartorius Aktiengesellschaft (XTRA:SRT) and Sartorius Stedim Biotech S.A. (ENXTPA:DIM) signed an agreement to acquire certain businesses from Danaher Corporation (NYSE:DHR) for approximately $750 million on October 18, 2019. The consideration will be paid in cash and will be subject to closing process. The business consists of label-free biomolecular characterization, chromatography hardware and resins, and microcarriers and particle validation standards businesses. The label-free biomolecular characterization business will become part of Sartorius’ bioanalytics unit within its Lab Products & Services division. The chromatography hardware and resins business will be part of Bioprocess Solutions division. Sartorius Stedim Biotech will acquire parts of Danaher’s Life Science portfolio. Out of the total purchase price of $750 million, about a quarter will be allocated to the businesses purchased by Sartorius Stedim Biotech. Pursuant to conditions set by the antitrust authorities, the portfolio of businesses to be acquired was expanded to include certain businesses associated with single-use tangential flow filtration systems (including flow kits) and stainless steel hollow fiber tangential flow filtration systems. These businesses will ultimately be a part of the Sartorius Bioprocess Solutions Division. Due to this expanded scope, the purchase price was increased by around $75 million to approximately $825 million. BNP Paribas is financing the transaction, acting as sole lead arranger, bookrunner and underwriter. The business reported revenues of approximately $140 million in 2018.
Danaher entered into the agreement to sell these businesses as a step towards obtaining regulatory approval for its pending acquisition of the Biopharma business of General Electric Company (NYSE:GE). The closing of this transaction is conditioned upon Danaher's closing its acquisition of the GE Biopharma business. The transaction is also subject to customary closing conditions, antitrust clearance and approvals from various regulatory authorities. In December 2019, the transaction received conditional clearance for the acquisition from the European Commission. On March 18, 2020 and March 19, 2020 respectively, the European Commission and the U.S. Federal Trade Commission cleared the proposed acquisition and the completion is still subject to clearance by the Chinese antitrust enforcement authority of Sartorius as the buyer of the assets. The transaction is expected to close in the first quarter of 2020. As of March 20, 2020, the transaction is expected to close in second quarter of 2020.
Michael P. Brueck, James Jian Hu, Francisco J. Morales Barrón and Daniel E. Wolf of Kirkland & Ellis LLP acted as legal advisors for Danaher. Michael Bernhardt, Roland Hlawaty, Scott Golenbock, Christoph Rothenfusser, Alexander Rinne and Fiona Schaeffer of Milbank LLP acted as legal advisor to Sartorius Aktiengesellschaft (XTRA:SRT) in the transaction. Johannes Tieves of Hengeler Mueller advised BNP Paribas on financing of the transaction.
Sartorius Aktiengesellschaft (XTRA:SRT) and Sartorius Stedim Biotech S.A. (ENXTPA:DIM) completed the acquisition of certain businesses from Danaher Corporation (NYSE:DHR) on April 30, 2020.